気管支拡張症治療薬としてのCFTR増強薬イセンチカフトル:国際共同第II相、二重盲検、ランダム化プラセボ対照試験
Wei-Jie Guan1,2, Charles S Haworth3, Harm A W M Tiddens4,5,6
1State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Joint International Research Laboratory of Respiratory Health, Guangdong Basic Research Center of Excellence for Respiratory Medicine, Department of Allergy and Clinical Immunology, Department of Respiratory and Critical Care Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510163, P. R. China.
No abstract available in PubMed .
関連する概念動画
Cystic Fibrosis: Management
Sinus disease and chronic...
Drugs for Treatment of Constipation-Predominant IBS
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
COPD: Management Using Bronchodilators and Corticosteroids
Chest Physiotherapy
Purpose
CPT is primarily used for patients with excessive bronchial secretions who have difficulty clearing...


